Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial

Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial

Abstract Background Uncontrolled/refractory gout patients are recalcitrant/intolerant to oral urate-lowering therapies (ULTs), experiencing frequent gout flares, functionally limiting tophi, and low quality of life. Pegloticase lowers urate, but anti-pegloticase antibodies limit urate-lowering effic...

Full description

Bibliographic Details
Main Authors: John K. Botson, Katie Obermeyer, Brian LaMoreaux, Lin Zhao, Michael E. Weinblatt, Jeff Peterson
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Arthritis Research & Therapy
Subjects:
Pegloticase
Uncontrolled gout
Refractory gout
Immunomodulation
Methotrexate
Online Access:https://doi.org/10.1186/s13075-022-02979-4

Internet

https://doi.org/10.1186/s13075-022-02979-4

Similar Items